Patient recruitment remains a significant challenge for biopharma companies, often leading to delays and increased costs in clinical trials. Traditional recruitment methods can be time-consuming ...

It comes as no surprise that more than 80% of clinical trials in the U.S fail to meet their patient enrolment times. The Patient Recruitment for Rare Disease Trials Summit addresses these ...

One major way AI is set to revolutionise clinical trials is by automating patient recruitment, which is typically the most ...

INR:6263. 23 tarikh ka lottery TaiGen Biopharma's new anti-influenza drug is approved for clinical trials in the U.S., without the restriction of taking the ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

INR:7155. singam lottery apps K drug/chemotherapy combination failed in phase III clinical trial of bladder cancer Transcenta's TST001 completed first patient ...

In contrast to manufacturing, clinical services outsourcing barely registers in public conversations about export diversification ...

satta matka cool Medical Talent Recruitment (Updated on 09.17) Runxin Biopharma's third-generation EGFR-TKI new drug completed the first patient in the pivotal registration phase 3 clinical trial Top ...

3 Secret Cities Arno Pharmaceuticals' Series C financing is nearly US$100 million to rapidly advance the global research and development of innovative tumor immunotherapy drugs REVLIMID is about to be ...

Marengo's Phase II trial is assessing T cell activator invikafusp alfa in the treatment of advanced PD-1 resistant solid tumours.

One major way AI is set to revolutionise clinical trials is by automating patient recruitment, which is typically the most time-consuming part of a clinical trial. The Biden administration on Monday ...

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.